Exploiting the promiscuity of imatinib
Author affiliations
1 Department of Medicine and Division of Hematology-Oncology, 3855 Health Sciences Drive, University of California, San Diego, La Jolla, CA 92093, USA
2 Moores Cancer Center, 3855 Health Sciences Drive, University of California, San Diego, La Jolla, CA 92093, USA
3 Division of Biological Sciences, 3855 Health Sciences Drive, University of California, San Diego, La Jolla, CA 92093, USA
Citation and License
Journal of Biology 2009, 8:30 doi:10.1186/jbiol134
Published: 15 April 2009Abstract
The protein kinase inhibitor imatinib, also known as Gleevec, has been a notable success in treating chronic myelogenous leukemia. A recent paper in BMC Structural Biology reports a 1.75 Å crystal structure of imatinib bound to the oxidoreductase NQO2 and reveals insights into the binding specificity and the off-target effects of the inhibitor.
